• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Bruin Biometrics conducts trials to detect pressure ulcers with the SEM Scanner

Bruin Biometrics conducts trials to detect pressure ulcers with the SEM Scanner

December 5, 2013
CenterWatch Staff

Bruin Biometrics (BBI) has announced results from two IRB-approved clinical trials conducted with the SEM Scanner, a Class IIA medical device that is intended to detect localized tissue edema and pressure induced tissue damage which may lead to the formation of pressure ulcers.

BBI enrolled 31 healthy subjects in a pilot study conducted in Los Angeles, Calif. to assess the reliability of the SEM Scanner. Results indicate that the SEM Scanner gives consistent readings and is reliable across different users and across different device models.

BBI also sponsored an investigational, non-significant risk study to collect data needed to analyze SEM Scanner readings at the University of Massachusetts Memorial Medical Center in Worcester, Massachusetts. Fifty subjects from the adult Critical Care Unit were enrolled in the trial and followed for five days. Although the medical center reports annual pressure ulcer incidence of 5.08%, zero subjects developed a pressure ulcer during the course of the BBI trial. Analysis of trial data is underway, and a final study report is expected in early 2014.

BBI will sponsor additional trials throughout 2014. The first will take place in the U.S. and will evaluate SEM Scanner readings in subjects with known pressure ulcers. A second study will enroll subjects throughout the U.S. and Europe in order to evaluate the SEM Scanner's effectiveness in lowering the incidence of pressure ulcers against the current standard of care.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing